Investment Strategy: Biologics LOE For institutional investors, the analytical question at a biologic LOE is not how much will biosimilars capture but rather: (1) what is the net price convergence trajectory between the reference product and biosimilar competitors under real-world formulary conditions, (2) does the innovator have pre-negotiated rebate contracts that lock in formulary position for 12 to 24 months post-launch, (3) what is the IP stack on the successor asset, and (4) how far along is the clinical conversion to a reformulated or combination version that carries fresh exclusivity
As the Medical Director of Sculpt Wellness, Rhonda has played a pivotal role in elevating the clinics reputation as a premier destination for personalized wellness solutions
In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease
With this, you have an affordable treatment provider that cares about your needs
A significant portion of trial participants were perimenopausal or postmenopausal women, showing consistent weight loss and metabolic improvements across age groups
In the first two weeks, your body is replenishing its stores